Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib plus endocrine therapy in the post-neoadjuvant surgical window for HR-positive/HER2-negative breast cancer
ChiCTR2600135680Phase 2Not yet recruiting
- Sponsor
- Huizhou Central People's Hospital
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dalpiciclib in breast cancer, sponsored by Huizhou Central People's Hospital. Primary endpoint: Complete cell cycle arrest rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600135680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135680.